复发性或耐火性扩散性大B细胞淋巴瘤的结果与二线化疗Ifosfamide-Carboplatin-Etoposide与或没有Rituximab
S Haque1, Z Z Chowdhury, T Bahar
1Dr Salina Haque, Assistant Professor, Department of Haematology, National Institute of Cancer Research and Hospital (NICR&H), Dhaka, Bangladesh;
Mymensingh medical journal : MMJ
|October 1, 2024
概括
用ICE或R-ICE疗法进行的救生化疗在复发或耐火性扩散大B细胞淋巴瘤患者中显示了64.8%的整体反应率. 然而,急需提高救援效率,需要进一步研究新的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 复发或不耐药的扩散性大B细胞淋巴瘤 (DLBCL) 存在重大治疗挑战.
- 最初的治疗反应强烈影响需要救援治疗的患者的结果.
- 对初级治疗不耐药的患者在随后的治疗中预后不好.
研究的目的:
- 评估二线ICE或R-ICE化疗在复发或耐药DLBCL的患者中的疗效.
- 评估这一患者队列的整体应答率,生存结果和预后因素.
主要方法:
- 一项观察性研究涉及34名患有复发或耐药DLBCL的患者.
- 患者接受ICE (28名患者) 或R-ICE (6名患者) 化疗作为二线治疗.
- 收集的数据包括应答率,总生存率和无进展生存率.
主要成果:
- 第二线化疗的整体响应率为64.8%,其中32.4%实现完全缓解,32.4%实现部分缓解.
- 平均总生存时间为10个月,4年总生存率为32.4%和4年无进展生存率为17.6%.
- 完全缓解 (15个月) 和部分缓解 (9个月) 与稳定/进展疾病 (7个月) 相比,与明显更好的中位数整体存活相关 (p<0.001).
- 国际预后指数 (IPI) 0-2的患者的平均整体存活率明显优于IPI>2 (p=0.010) 的患者.
结论:
- ICE或R-ICE化疗在复发性或耐火性DLBCL中提供了适度的响应率,但强调了迫切需要更有效的救援疗法.
- 预测因素,如初始反应和IPI得分,对于预测结果至关重要.
- 对新型治疗剂的进一步研究对于改善这些具有挑战性的病例的存活率至关重要.
相关概念视频
01:27Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K